Remove Finance Remove Initial Public Offering Remove Public Trading
article thumbnail

Is Private Equity Right for You?

OfficeHours

Private equity involves investing capital directly into private businesses that are not publicly traded on stock exchanges (that would be a hedge fund). Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank.

article thumbnail

08-20-2023 Newsletter: Sunday Reading

OfficeHours

Private equity involves investing capital directly into private businesses that are not publicly traded on stock exchanges (that would be a hedge fund). Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

“To the Moon”: The Rise of the Retail Investor and What this Means for Dealmakers

Deal Law Wire

Many factors affect a private company’s decision to go public – whether through initial public offerings or “go-public” M&A transactions – including being the target of a reverse takeover or a special purpose acquisition company. Private Companies. Conclusion.

Retail 40
article thumbnail

Dual-Track Processes: How to Turbocharge Your Exit

Cooley M&A

In the face of a global economic slowdown, ongoing trade wars, Brexit, heightened market volatility and other sources of uncertainty, it is becoming increasingly important to consider how deals can be run to maximize transaction certainty and achieve optimal valuation. Is the objective to achieve a partial or complete exit?

IPO 52
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]

M&A 52
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market.

M&A 64